

A guide to Endometrium Cancer Histopathology Reporting



Clinical details		Macroscopic findings (cont.)	
S1.02	Pathology accession number	Text	
S1.03	Principal clinician	Text	
S1.04	Operative procedure/specimen	Total hysterect. Subtotal hyster. Radical hyster.	
	Accompanying specimens	Text	
G1.04	Clinical/differential diagnoses	Text	
G1.05	Previous biopsies & cytology results (include testing laboratory)	Text	
G1.06	Any previous or current treatment of the present tumour	Text	
G1.07	Any other prior cancer diagnosis	Text	
G1.08	Any family history of cancer	Text	
S1.05	Metastatic disease?	Not stated Absent Present	
	If present, was it...	Pre-operative Intra-operative	
	If present, give details	Text	
S1.06	Post-operative residual tumour	Not stated Absent Present	
	If present, give details	Text	
G1.09	Surgeon's specific remarks	Text	
Macroscopic findings			
S2.04	Lymph nodes - <i>per site</i>:		
	Description	Text	
	Total nbr nodes	___	
	Max. diameter/range	___to___mm	
S2.05	Omentum:		
	Dimensions	___x___x___mm	
	Proportion of fat replaced by tumour	___% (est.)	
	Description	Text	
S2.06	Peritoneal biopsies - <i>per site</i>:		
	Dimensions	___x___x___mm	
	Description	Text	
S2.07	Left ovary:		
	Surface	Text	
	Dimensions	___x___x___mm	
	Description	Text	
	Right ovary:		
	Surface	Text	
	Dimensions	___x___x___mm	
	Description	Text	
S2.08	Left fallopian tube:		
	Dimensions (length x max. diameter)	___x___mm	
	Description	Text	
	Right fallopian tube:		
	Dimensions (length x max. diameter)	___x___mm	
	Description	Text	
S2.09	External appearance of uterus:		
	Uterus received	Intact Opened	
	Serosal surface	Text	
S2.10	Weight of uterus	___g	
S2.11	Measurements of uterus:		
	midline fundal-serosa to ectocervix	___mm	
	max. intercornual	___mm	
	max. anterior to posterior	___mm	
	Gross description	Text	
S2.12	Site of tumour	See p2	
	Tumour dimensions (superior-inferior x transverse x thickness where thickness = exophytic + endophytic)	___x___x___mm	
G2.05	Distance of endometrial tumour from the inferior surgical margin	___mm	
S2.13	Paraffin block identificatn. key	Text	
S2.14	Gross depth of maximal myometrial invasion	___mm	
	Thickness of normal (uninvolved) myometrial wall	___mm	
S2.15	Cervical tissues	Description	
	If tumour present record		
	Dimensions	___x___x___mm	
	Distance from the inferior surgical margin	___mm	
	Max. depth of cervical wall invasion	___mm	
	Thickness of uninvolved cervical wall	___mm	
G2.06	Other macroscopic comment	Text	
Microscopic findings			
S3.01	Lymph node involvement by tumour - <i>per site</i>		
	Nbr of involved nodes	___	
	Nbr nodes resected	___	
	Max. dimension of metastasis/size range	___to___mm	
	Extranodal spread	Absent Present	
S3.02	Omental involvement	Tumour free Involved	
	If involved, describe	Text	
S3.03	Peritoneal involvement	Tumour free Involved	
	If involved, describe	Text	
S3.04	Ovarian involvement	Tumour free Involved	
	If involved, describe	Text	
S3.05	Fallopian tubal involvement	Tumour free Involved	
	If involved, describe	Text	
S3.06	Histological tumour type	See p2	

Microscopic findings (cont.)

S3.07	Histological grade:	
	FIGO	Grade 1 Grade 2 Grade 3 Grading NA
	Other grading system	Text
G3.02	Year of publication of grading system	_____
S3.08	Maximum microscopic depth of myometrial invasion	____mm Slide nbr
	Normal myometrial wall thickness	____mm
S3.09	Lymphovascular invasion	Absent Present
	If present, was it...	At tumour int'face Remote
	If remote, specify dist. from tumour face	____mm
S3.10	Involvement of cervical mucosa only	Absent Present
	If present is it...	In continuity Separate
	Cervical stroma involvement	Absent Present
	If present is it...	In continuity Separate
	If present, record the max. invasive depth	____mm Slide nbr
	normal cervical wall thickness	____mm
	Cervical vascular involvement:	Absent Present
S3.11	Residual non-tumourous endometrium	Atrophic/cycle phase Hyperplastic Atypical hyperplast.
	Description (eg polyps)	Text
	In situ carcinoma	Absent Present
	Multicentric/multifocal carcinoma:	Absent Present
	If present, record:	Histological type Extent Sites
G3.03	Other microscopic comments	Text

Ancillary test findings

G4.01	Histochemical stains	Text
G4.02	For immunohistochemical stains, record	Each antibody Result Interpretation Clin. significance

Synthesis and overview

S5.01	Tumour stage (FIGO)	See p2
	Pathologic tumour stage (TNM)	See p2
S5.02	Year of publication & edition of cancer staging system	Text
G5.01	Residual tumour status	RX R0 R1 R2

Synthesis and overview (cont.)

G5.02	Diagnostic summary (Include: operative procedure/ specimen type (S1.03); tumour type (S3.06); tumour stage (S5.01); residual tumour status (G5.01)	Text
S5.03	Other relevant comments	Text

NOTES

S2.12 Site of tumour

- anterior endometrium
- posterior endometrium
- fundal endometrium
- left or right cornual recess
- isthmus

S3.06 Histologic tumour type

- Endometrioid adenocarcinoma
- and variant
- Mucinous adenocarcinoma
- Serous carcinoma
- Clear cell carcinoma
- Carcinosarcoma
- Undifferentiated carcinoma
- Other tumour type (state)
- Mixed types of endometrial carcinomas (state all and relative percentage)

S5.01 Tumour stage FIGO & pTNM#

Primary Tumour (T) (Surgical-Pathologic Findings)		
TNM	FIGO	
TX		Primary tumour cannot be assessed
T0		No evidence of primary tumour
Tis*		Carcinoma in situ (preinvasive carcinoma)
T1	I	Tumour confined to corpus uteri
T1a	IA	Tumour limited to endometrium or invades less than one-half of the myometrium
T1b	IB	Tumour invades one-half or more of the myometrium
T2	II	Tumour invades stromal connective tissue of the cervix but does not extend beyond uterus**
T3a	IIIA	Tumour involves serosa and /or adnexa (direct extension or metastasis)
T3b	IIIB	Vaginal involvement (direct extension or metastasis) or parametrial involvement.
T4	IVA	Tumour invades bladder mucosa and /or bowel mucosa (bullous oedema is not sufficient to classify a tumour as T4)
Regional Lymph Nodes (N)		
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1	IIIC1	Regional lymph nodes metastasis to pelvic lymph nodes
N2	IIIC2	Regional lymph nodes metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.
Distant Metastasis (M)		
M0		No distant metastasis
M1	IVB	Distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone. It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa.

* Note: FIGO no longer includes Stage 0(Tis)

** Endocervical glandular involvement only should be considered Stage I and not as Stage II.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com.